The U.S. breast imaging and mammography markets are expected to not only recover from the recession, but nearly double in the next several years.
The U.S. breast imaging and mammography markets are expected to not only recover from the recession, but nearly double in the next several years.
By 2017, the markets are expected to reach more than $1 billion, according to a new report by iData Research, a medical device and pharmaceutical market research company. The growth is expected to be driven by the replacement of older analog equipment with technologies such as digital radiography, breast-specific gamma imaging, positron emission mammography, and ultrasound equipment.
Leading the overall $2.3 billion women’s health market with sales of digital radiography equipment are Hologic and GE Healthcare, the report found. The development of breast-specific gamma imaging by Dilon Technologies and Gamma Medical, and positron emission mammography by Naviscan mean a new market for breast scans, and these technologies will experience “rapid growth,” according to Dr. Kamran Zamanian, CEO of iData.
“The majority of analog units used in 2010 are expected to be replaced by 2017,” Zamanian said in a statement.
Study Reaffirms Low Risk for csPCa with Biopsy Omission After Negative Prostate MRI
December 19th 2024In a new study involving nearly 600 biopsy-naïve men, researchers found that only 4 percent of those with negative prostate MRI had clinically significant prostate cancer after three years of active monitoring.
Study Examines Impact of Deep Learning on Fast MRI Protocols for Knee Pain
December 17th 2024Ten-minute and five-minute knee MRI exams with compressed sequences facilitated by deep learning offered nearly equivalent sensitivity and specificity as an 18-minute conventional MRI knee exam, according to research presented recently at the RSNA conference.
Can Radiomics Bolster Low-Dose CT Prognostic Assessment for High-Risk Lung Adenocarcinoma?
December 16th 2024A CT-based radiomic model offered over 10 percent higher specificity and positive predictive value for high-risk lung adenocarcinoma in comparison to a radiographic model, according to external validation testing in a recent study.